glp-1 incretin Receptor Agonists GIP and GLP-1 as incretin

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Advances in Therapy, vol

October 2025, Janet Iwasa

Why the Eyes Matter in GLP-1 Treatment Can GLP-1 Drugs Worsen Diabetic Retinopathy

Tirzepatide: the dual-action option Tirzepatide is a dual GLP-1/GIP receptor agonist

For an 8mg dose from this vial concentration, you would need 1.6ml, which exceeds the capacity of a single 1ml syringe, requiring either a larger reconstitution volume or two separate draws

1 However, depending on the form taken, these medications can cause a slew of unwanted effects ranging from nausea and vomiting to lean muscle loss